These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 20332030)

  • 1. Colonoscopic method for estimating the colonic absorption of extended-release dosage forms in dogs.
    Tajiri S; Kanamaru T; Yoshida K; Hosoi Y; Fukui S; Konno T; Yada S; Nakagami H
    Eur J Pharm Biopharm; 2010 Jun; 75(2):238-44. PubMed ID: 20332030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical approaches to colon targeted drug delivery systems.
    Chourasia MK; Jain SK
    J Pharm Pharm Sci; 2003; 6(1):33-66. PubMed ID: 12753729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of an in vitro faecal degradation method for early assessment of the impact of colonic degradation on colonic absorption in humans.
    Tannergren C; Borde A; Boreström C; Abrahamsson B; Lindahl A
    Eur J Pharm Sci; 2014 Jun; 57():200-6. PubMed ID: 24514453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between the drug concentration profiles in plasma and the drug doses in the colon.
    Tajiri S; Kanamaru T; Yoshida K; Hosoi Y; Konno T; Yada S; Nakagami H
    Chem Pharm Bull (Tokyo); 2010 Oct; 58(10):1295-300. PubMed ID: 20930393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of absorption promoters on insulin absorption through colon-targeted delivery.
    Katsuma M; Watanabe S; Kawai H; Takemura S; Sako K
    Int J Pharm; 2006 Jan; 307(2):156-62. PubMed ID: 16289574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment.
    Tannergren C; Bergendal A; Lennernäs H; Abrahamsson B
    Mol Pharm; 2009; 6(1):60-73. PubMed ID: 19183105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro and in vivo evaluations of oral sustained-release formulations of diclofenac sodium in beagle dogs.
    Medeiros DC; Mazon-Cardoso T; Lemos-Senna E; Poli A
    Pharmazie; 2009 Oct; 64(10):648-52. PubMed ID: 19947166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low colonic absorption drugs: risks and opportunities in the development of oral extended release products.
    Xu J; Lin Y; Boulas P; Peterson ML
    Expert Opin Drug Deliv; 2018 Feb; 15(2):197-211. PubMed ID: 28988504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of food intake on the delivery of fluorescein as a model drug in colon delivery capsule after oral administration to beagle dogs.
    Matsuda K; Takaya T; Shimoji F; Muraoka M; Yoshikawa Y; Takada K
    J Drug Target; 1996; 4(2):59-67. PubMed ID: 8894965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained delivery of intact drug to the colon: mesalamine formulation and temporal gastrointestinal transit analysis.
    Chuong MC; Christensen JM; Ayres JW
    Pharm Dev Technol; 2009; 14(1):116-25. PubMed ID: 18821272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an azopolymer based colonic release capsule for delivering proteins/macromolecules.
    Cheng CL; Gehrke SH; Ritschel WA
    Methods Find Exp Clin Pharmacol; 1994 May; 16(4):271-8. PubMed ID: 8051987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical models for colonic absorption, application to controlled release formulation development.
    Lozoya-Agullo I; González-Álvarez I; Merino-Sanjuán M; Bermejo M; González-Álvarez M
    Eur J Pharm Biopharm; 2018 Sep; 130():247-259. PubMed ID: 30064699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral modified-release formulations in motion: the relationship between gastrointestinal transit and drug absorption.
    Varum FJ; Merchant HA; Basit AW
    Int J Pharm; 2010 Aug; 395(1-2):26-36. PubMed ID: 20546855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a colonic release capsule dosage form and the absorption of insulin.
    Kraeling ME; Ritschel WA
    Methods Find Exp Clin Pharmacol; 1992 Apr; 14(3):199-209. PubMed ID: 1378164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AC biosusceptometry in the study of drug delivery.
    Corá LA; Romeiro FG; Stelzer M; Américo MF; Oliveira RB; Baffa O; Miranda JR
    Adv Drug Deliv Rev; 2005 Jun; 57(8):1223-41. PubMed ID: 15935871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral colon delivery: rationale and time-based drug design strategy.
    Gazzaniga A; Maroni A; Foppoli A; Palugan L
    Discov Med; 2006 Dec; 6(36):223-8. PubMed ID: 17250787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical design of a novel colon-targeted delivery system using two-layer-coated tablets of three different pharmaceutical formulations, supported by clinical evidence in humans.
    Goto T; Tanida N; Yoshinaga T; Sato S; Ball DJ; Wilding IR; Kobayashi E; Fujimura A
    J Control Release; 2004 May; 97(1):31-42. PubMed ID: 15147802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulations and dosages of oral drugs.
    Calesnick B
    Am Fam Physician; 1978 Sep; 18(3):160-2. PubMed ID: 685796
    [No Abstract]   [Full Text] [Related]  

  • 19. The bioavailability of oral dosage forms of a new HIV-1 protease inhibitor, KNI-272, in beagle dogs.
    Kiriyama A; Sugahara M; Yoshikawa Y; Kiso Y; Takada K
    Biopharm Drug Dispos; 1996 Mar; 17(2):125-34. PubMed ID: 8907719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses.
    Garbacz G; Wedemeyer RS; Nagel S; Giessmann T; Mönnikes H; Wilson CG; Siegmund W; Weitschies W
    Eur J Pharm Biopharm; 2008 Oct; 70(2):421-8. PubMed ID: 18582568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.